ES2089782T3 - Imidazolalquilo sustituido con un anillo heterociclico que contiene nitrogeno de seis elementos. - Google Patents

Imidazolalquilo sustituido con un anillo heterociclico que contiene nitrogeno de seis elementos.

Info

Publication number
ES2089782T3
ES2089782T3 ES93901399T ES93901399T ES2089782T3 ES 2089782 T3 ES2089782 T3 ES 2089782T3 ES 93901399 T ES93901399 T ES 93901399T ES 93901399 T ES93901399 T ES 93901399T ES 2089782 T3 ES2089782 T3 ES 2089782T3
Authority
ES
Spain
Prior art keywords
compound
formula
disclosed
imidazolalkyl
hetero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93901399T
Other languages
English (en)
Inventor
Neng-Yang Shih
Michael J Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2089782T3 publication Critical patent/ES2089782T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Materials For Medical Uses (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE DESCRIBE UN COMPUESTO DE FORMULA (1.0) O UNA SAL FARMACEUTICAMENTE ACEPTABLE O DISOLUCION DE EL. TAMBIEN SE DESCRIBEN COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UN PORTADOR ACEPTABLE FARMACEUTICAMENTE Y UNA CANTIDAD EFECTIVA DE UN COMPUESTO DE FORMULA (1.0). ADICIONALMENTE SE DESCRIBE UN METODO DE TRATAR ALERGIA (POR EJEMPLO ASMA), INFLAMACION, HIPERTENSION, PRESION INTRAOCULAR ELEVADA (TAL COMO GLAUCOMA), P.E., UN METODO DE REDUCIR PRESION INTRAOCULAR, DESORDENES DEL SUEÑO, ESTADOS DE HIPER E HIPO MOVILIDAD Y SECRECION ACIDA DEL TRACTO GASTROINTESTINAL, HIPO E HIPERACTIVIDAD DEL SISTEMA NERVIOSO CENTRAL (POR EJEMPLO, AGITACION Y DEPRESION) Y OTROS DESORDENES (TALES COMO ALZHEIMER, ESQUIZOFRENIA, Y MIGRAÑA) COMPRENDE ADMINISTRAR UNA CANTIDAD EFECTIVA DE UN COMPUESTO DE FORMULA (1.0) A UN PACIENTE EN NECESIDAD DE TAL TRATAMIENTO.
ES93901399T 1991-12-18 1992-12-16 Imidazolalquilo sustituido con un anillo heterociclico que contiene nitrogeno de seis elementos. Expired - Lifetime ES2089782T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81065191A 1991-12-18 1991-12-18

Publications (1)

Publication Number Publication Date
ES2089782T3 true ES2089782T3 (es) 1996-10-01

Family

ID=25204344

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93901399T Expired - Lifetime ES2089782T3 (es) 1991-12-18 1992-12-16 Imidazolalquilo sustituido con un anillo heterociclico que contiene nitrogeno de seis elementos.

Country Status (19)

Country Link
EP (1) EP0619818B1 (es)
JP (1) JPH07121938B2 (es)
KR (1) KR0142801B1 (es)
AT (1) ATE140223T1 (es)
AU (1) AU665604B2 (es)
CA (1) CA2126086C (es)
DE (1) DE69212164T2 (es)
DK (1) DK0619818T3 (es)
ES (1) ES2089782T3 (es)
GR (1) GR3021195T3 (es)
HK (1) HK31097A (es)
IL (1) IL104124A (es)
MX (1) MX9207392A (es)
MY (1) MY108904A (es)
NZ (1) NZ246434A (es)
SG (1) SG44565A1 (es)
TW (1) TW263503B (es)
WO (1) WO1993012107A1 (es)
ZA (1) ZA929785B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9302045A (nl) * 1993-08-27 1995-03-16 Vrije Universiteit Nieuwe imidazoolafgeleide met agonistische of antagonistische activiteit op de histamine H3-receptor.
AU7823894A (en) * 1993-08-27 1995-03-21 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
JP2000500502A (ja) * 1995-11-22 2000-01-18 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
CA2250353A1 (en) * 1996-04-03 1997-10-09 Christopher J. Dinsmore Inhibitors of farnesyl-protein transferase
US6072057A (en) * 1996-06-06 2000-06-06 Gliatech Inc. 1H-4(5)-cyclo-substituted imidazole derivatives as histamine H3 receptor agents
US6407132B1 (en) 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
US6034251A (en) * 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
EP1028956A1 (en) * 1997-11-07 2000-08-23 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
PL341009A1 (en) * 1997-12-04 2001-03-12 Allergan Sales Substitute derivatives of imidazole exhibiting agonist-like activity in respect to adrenergic alpha 2b or 2b/2c receptors
US6133291A (en) * 1998-10-16 2000-10-17 Schering Corporation N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
US6100279A (en) * 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
WO2000042023A1 (en) 1999-01-18 2000-07-20 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6211182B1 (en) * 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
WO2002013821A1 (en) 2000-08-17 2002-02-21 Gliatech, Inc. Novel alicyclic imidazoles as h3 agents
JPWO2003070722A1 (ja) 2002-02-21 2005-06-09 アルフレッサファーマ株式会社 イミダゾール誘導体の改良製法およびその新規中間体
EP1707203A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EP1717233A1 (en) 2005-04-29 2006-11-02 Bioprojet Histamine H3-receptor ligands and their therapeutic application
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
DE602007011793D1 (de) 2006-10-18 2011-02-17 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US11114499B2 (en) 2018-01-02 2021-09-07 Seoul Viosys Co., Ltd. Display device having light emitting stacked structure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2586562B1 (fr) * 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
EP0372125A1 (en) * 1988-11-08 1990-06-13 Akzo N.V. Oxazole and thiazole derivatives
US4925851A (en) * 1989-05-23 1990-05-15 Sandoz Pharmaceuticals Corp. 2- or 4-substituted-[2-(1H-imidazol-1-yl)ethyl]piperidines

Also Published As

Publication number Publication date
TW263503B (es) 1995-11-21
DE69212164T2 (de) 1996-12-05
KR940703827A (es) 1994-12-12
CA2126086A1 (en) 1993-06-24
JPH07121938B2 (ja) 1995-12-25
WO1993012107A1 (en) 1993-06-24
IL104124A (en) 1998-12-06
AU665604B2 (en) 1996-01-11
DK0619818T3 (da) 1996-11-25
ATE140223T1 (de) 1996-07-15
AU3275893A (en) 1993-07-19
KR0142801B1 (en) 1998-07-15
IL104124A0 (en) 1993-05-13
MX9207392A (es) 1993-06-01
GR3021195T3 (en) 1996-12-31
NZ246434A (en) 1996-02-27
JPH06511252A (ja) 1994-12-15
MY108904A (en) 1996-11-30
EP0619818A1 (en) 1994-10-19
SG44565A1 (en) 1997-12-19
DE69212164D1 (de) 1996-08-14
CA2126086C (en) 2000-03-28
ZA929785B (en) 1993-06-21
HK31097A (en) 1997-03-21
EP0619818B1 (en) 1996-07-10

Similar Documents

Publication Publication Date Title
ES2089782T3 (es) Imidazolalquilo sustituido con un anillo heterociclico que contiene nitrogeno de seis elementos.
ES2090956T3 (es) Imidazolil o imidazolilalquil sustituido con un anillo heterociclico de cuatro o cinco miembros que contiene nitrogeno.
TW268951B (es)
ATE45941T1 (de) Medizinische zusammensetzung zur behandlung von allergie-krankheiten.
SE8801845L (sv) Farmakologiskt aktiva substituerade bensa mider
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
NO172640C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive piperazinderivater
WO1999024421A8 (en) Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
SE9702716D0 (sv) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
ATE186215T1 (de) Verwendung von n-(pyridinyl)-1h-indol-1-aminen zur herstellung eines medikamentes zur behandlung von zwangsneurotischen erkrankungen
ECSP982727A (es) Imidazol ilalquilo sustituido con un anillo heterociclico de cinco, seis o siete miembros que contienen un atomo de nitrogeno (caso al 0797k)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 619818

Country of ref document: ES

FG2A Definitive protection

Ref document number: 619818

Country of ref document: ES